CalciMedica's 2025 Financial Results and Promising Clinical Updates on Novel Therapies CalciMedica Inc. has reported its financial results for 2025 while providing significant updates on its clinical trials, including promising therapies for acute kidney injury and pancreatitis.

CalciMedica's 2025 Financial Results and Promising Clinical Updates on Novel Therapies #USA #La_Jolla #CalciMedica #Auxora #CM5480

CalciMedica Reveals Promising Data on CRAC Channel Inhibitor for Pulmonary Arterial Hypertension CalciMedica has announced exciting new preclinical findings regarding CM5480, a CRAC channel inhibitor, as a potential breakthrough treatment for pulmonary arterial hypertension.

CalciMedica Reveals Promising Data on CRAC Channel Inhibitor for Pulmonary Arterial Hypertension #USA #La_Jolla #CalciMedica #CRAC_channel #CM5480